Generic Viibryd ( Vilazodone )

Order cheap Generic Viibryd (Vilazodone) without dr prescription in the United States

In our USA pharmacy, you can buy Viibryd without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Viibryd (vilazodone) is a serotonin partial agonist and reuptake inhibitor (SPARI) used to treat major depressive disorder (MDD) in adults. It combines selective serotonin reuptake inhibition with partial agonism at the 5‑HT1A receptor, a dual mechanism thought to provide antidepressant efficacy with a potentially faster onset of action than conventional SSRIs.
Usual adult dose: Start with 10 mg once daily with food for 7 days, then increase to 20 mg once daily with food. The dose may be increased up to 40 mg once daily after a minimum of 7 days between dose increases. The recommended target dosage is 20 mg to 40 mg once daily.
Dosage form: Film‑coated oral tablets (10 mg, 20 mg, 40 mg).
Onset of action: Some patients may experience initial improvement within 1‑2 weeks; full therapeutic effect typically develops over 8 weeks.
Duration of action: Once‑daily dosing with food maintains steady‑state plasma levels (elimination half‑life approximately 25 hours).
Alcohol consumption should be limited or avoided; combining alcohol with vilazodone may increase the risk of central nervous system depression, worsen depressive symptoms, and elevate the likelihood of gastrointestinal side effects such as nausea and diarrhea.
Most common side effects: diarrhea, nausea, vomiting, and insomnia (incidence ≥ 5% and at least twice the rate of placebo).
Would you like to try Viibryd without a prescription?

General Information about Viibryd

• INN (International Nonproprietary Name): Vilazodone hydrochloride
• Brand names available in the USA: Viibryd® (brand originally marketed by Allergan, now AbbVie Inc.); FDA‑approved generic versions manufactured by Teva Pharmaceuticals USA, Inc., Accord Healthcare Inc., Alembic Pharmaceuticals, Apotex Corp., and Invagen Pharmaceuticals Inc.
• ATC code: N06AX24
• Dosage forms and strengths: Film‑coated tablets: 10 mg, 20 mg, and 40 mg.
• Manufacturers in USA: AbbVie Inc. (brand Viibryd®); Teva Pharmaceuticals USA, Inc.; Accord Healthcare Inc.; Alembic Pharmaceuticals; Apotex Corp.; Invagen Pharmaceuticals Inc.
• Registration status in USA: Approved by the U.S. Food and Drug Administration (FDA) on January 21, 2011 (NDA 022567).
• OTC / Rx classification: Prescription only (Rx). DEA Schedule: None.

Mechanism of Action and Pharmacology

Vilazodone is a combined serotonin partial agonist and reuptake inhibitor (SPARI), representing a distinct pharmacological class among antidepressants. Its mechanism of action is dual: it potently and selectively inhibits the serotonin transporter (SERT), blocking the reuptake of serotonin (5‑HT) from the synaptic cleft — the classic mechanism of SSRIs — while simultaneously acting as a high‑affinity partial agonist at the 5‑HT1A receptor. At presynaptic 5‑HT1A autoreceptors, vilazodone's partial agonism may accelerate desensitization of these inhibitory receptors, thereby disinhibiting serotonergic neuronal firing more rapidly than conventional SSRIs. At postsynaptic 5‑HT1A receptors, the partial agonist activity provides direct serotonergic stimulation. This dual action is theorized to result in enhanced serotonergic neurotransmission, potentially translating to a faster onset of antidepressant effect and improved tolerability compared with agents that solely inhibit serotonin reuptake. Vilazodone is extensively metabolized in the liver, primarily via CYP3A4, with minor contributions from CYP2C19 and CYP2D6. Oral bioavailability is approximately 72% when administered with food but decreases by approximately 50% under fasting conditions; therefore, dosing with a meal is essential. Peak plasma concentrations are reached in about 4‑5 hours, and the elimination half‑life is approximately 25 hours, supporting once‑daily administration. Steady‑state concentrations are achieved in approximately 3 days. Vilazodone is highly protein‑bound (96‑99%).

Indications

• Treatment of major depressive disorder (MDD) in adults.
• Off‑label uses (not FDA‑approved): generalized anxiety disorder, post‑traumatic stress disorder, and separation anxiety disorder — clinical evidence is emerging but not yet sufficient for formal regulatory approval.

Important Warnings and Precautions

VIIBRYD CARRIES A BOXED WARNING FOR SUICIDAL THOUGHTS AND BEHAVIORS. Antidepressants, including vilazodone, increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18‑24) during initial treatment. Closely monitor all antidepressant‑treated patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the first few months of therapy and at times of dose changes. Viibryd is not approved for use in pediatric patients. Serotonin syndrome, a potentially life‑threatening condition, may occur with vilazodone, particularly when used concomitantly with other serotonergic agents (SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort) but also when taken alone. Symptoms include mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (hyperreflexia, incoordination), and/or gastrointestinal symptoms (nausea, vomiting, diarrhea). Discontinue vilazodone and initiate supportive treatment if serotonin syndrome occurs. Vilazodone may increase the risk of bleeding events, particularly when co‑administered with aspirin, nonsteroidal anti‑inflammatory drugs (NSAIDs), warfarin, or other anticoagulants and antiplatelet agents. Activation of mania or hypomania may occur; screen patients for bipolar disorder and personal/family history of mania prior to initiating therapy. Discontinuation syndrome (dysphoric mood, irritability, agitation, dizziness, sensory disturbances, confusion, headache, insomnia) may occur upon abrupt cessation; gradual dose reduction is recommended when discontinuing therapy. Seizures have been reported; use with caution in patients with a history of seizure disorder. Vilazodone may cause mydriasis and should be avoided in patients with untreated anatomically narrow angles (angle‑closure glaucoma). Hyponatremia, possibly due to syndrome of inappropriate antidiuretic hormone secretion (SIADH), has been reported; caution is advised in elderly patients and those who are volume‑depleted or taking diuretics. Sexual dysfunction, including decreased libido, erectile dysfunction, and delayed ejaculation, may occur with vilazodone, although rates may be lower compared with conventional SSRIs.

At‑risk groups

• Elderly: No dose adjustment is recommended based solely on age. However, elderly patients may be at increased risk of hyponatremia and bleeding; monitor closely. Clinical studies did not include sufficient numbers of patients aged 65 and over to determine differential response.
• Pregnancy: There are no adequate and well‑controlled studies of vilazodone in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants exposed to serotonergic antidepressants late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Pregnant women exposed to vilazodone are encouraged to enroll in the National Pregnancy Registry for Antidepressants.
• Breastfeeding: It is not known whether vilazodone is excreted in human milk. In animal studies, vilazodone was excreted into the milk of lactating rats. Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment. A decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
• Renal impairment: No dose adjustment is required in patients with mild, moderate, or severe renal impairment. Vilazodone has not been studied in patients with end‑stage renal disease (ESRD).
• Hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment (Child‑Pugh A or B). Vilazodone has not been studied in patients with severe hepatic impairment (Child‑Pugh C); use with caution.
• Pediatric: Safety and efficacy have not been established in pediatric patients. Viibryd is not approved for use in individuals under 18 years of age.
• Bipolar disorder: Screen for personal or family history of bipolar disorder, mania, or hypomania before initiating treatment.
• Seizure disorders: Use with caution in patients with a history of seizures or conditions that lower the seizure threshold.

Driving and alcohol

Vilazodone may impair judgment, thinking, and motor skills. Patients should use caution when driving or operating hazardous machinery until they have gained sufficient experience with the drug to determine its effect on their cognitive and motor performance. Alcohol consumption should be limited or avoided entirely during treatment. Alcohol may worsen depressive symptoms, potentiate central nervous system depression, impair cognitive and motor function, and increase the risk of gastrointestinal side effects (particularly nausea and diarrhea). Heavy alcohol intake, especially in combination with vilazodone, may also increase the risk of hepatic injury.

Dosage Instructions

• Recommended target dosage: 20 mg to 40 mg orally once daily with food.
• Titration schedule: Start with 10 mg once daily with food for 7 days, then increase to 20 mg once daily with food. If further clinical response is needed, the dose may be increased up to 40 mg once daily with food, with a minimum of 7 days between dose increases.
• Administration: Must be taken with food to ensure adequate absorption. Bioavailability decreases by approximately 50% when taken on an empty stomach.
• Missed dose: If a dose is missed, take it as soon as remembered. If it is almost time for the next dose, skip the missed dose and resume the regular schedule. Do not take two doses at the same time.
• Dose adjustment with strong CYP3A4 inhibitors: When co‑administered with strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, voriconazole), the vilazodone dose should not exceed 20 mg once daily. The original dose may be resumed when the CYP3A4 inhibitor is discontinued.
• Dose adjustment with strong CYP3A4 inducers: When co‑administered with strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin) for more than 14 days, consider increasing the vilazodone dose up to 2‑fold, to a maximum of 80 mg once daily, over 1‑2 weeks. Gradually reduce the dose to the original level over 1‑2 weeks when the CYP3A4 inducer is discontinued.
• Discontinuation: Gradually reduce the dose whenever possible to minimize discontinuation symptoms. Taper from 40 mg once daily to 20 mg once daily for 4 days, followed by 10 mg once daily for 3 days. Patients on 20 mg once daily should be tapered to 10 mg once daily for 7 days.
• Switching to or from MAOIs: At least 14 days must elapse between discontinuation of an MAOI antidepressant and initiation of vilazodone, and at least 14 days between stopping vilazodone and starting an MAOI.

Side Effects and Contraindications

Most common adverse reactions (incidence ≥ 5% and at least twice the rate of placebo): diarrhea (28‑35%), nausea (23‑26%), vomiting (5‑8%), and insomnia (6‑7%). Gastrointestinal side effects are most prominent during the first week of therapy and tend to diminish with continued treatment.
Other common adverse reactions: dry mouth, dizziness, abnormal dreams, fatigue, decreased libido, delayed ejaculation, erectile dysfunction, somnolence, and increased sweating.
Serious adverse reactions: Serotonin syndrome (mental status changes, autonomic instability, neuromuscular symptoms, seizures); suicidal thoughts and behaviors, particularly in young adults; activation of mania/hypomania; clinically significant bleeding events (gastrointestinal bleeding, ecchymosis, epistaxis, petechiae); hyponatremia (especially in elderly and volume‑depleted patients); seizures; angle‑closure glaucoma; and discontinuation syndrome upon abrupt cessation.
Postmarketing experience: Sleep paralysis, hallucinations, suicide attempt, suicidal ideation, irritability, rash, urticaria, drug eruption, acute pancreatitis, anosmia, and hyposmia have been reported voluntarily.
Absolute contraindications: Concomitant use of monoamine oxidase inhibitors (MAOIs), including linezolid and intravenous methylene blue, or use within 14 days of stopping MAOIs, due to increased risk of serotonin syndrome.

Drug Interactions

• Monoamine oxidase inhibitors (MAOIs): Contraindicated. Concomitant use significantly increases the risk of serotonin syndrome. Separate use by at least 14 days.
• Other serotonergic drugs (e.g., SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids including fentanyl, lithium, buspirone, amphetamines, tryptophan, and St. John's Wort): Increased risk of serotonin syndrome. Monitor carefully; if serotonin syndrome occurs, discontinue vilazodone and/or the concomitant serotonergic agent.
• Antiplatelet agents and anticoagulants (e.g., aspirin, NSAIDs, clopidogrel, warfarin, heparin, direct oral anticoagulants): Serotonin release by platelets plays an important role in hemostasis. Concomitant use may potentiate the risk of bleeding. Carefully monitor INR in patients taking warfarin.
• Strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, clarithromycin, voriconazole, ritonavir): Significantly increase vilazodone exposure. The vilazodone dose should not exceed 20 mg once daily during co‑administration.
• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's Wort): Significantly decrease vilazodone exposure, potentially reducing efficacy. Consider increasing the vilazodone dose up to 2‑fold (maximum 80 mg/day) over 1‑2 weeks when inducers are used for more than 14 days.
• Highly protein‑bound drugs: Vilazodone is highly protein‑bound; co‑administration with other highly protein‑bound drugs may cause increased free concentrations of one or both agents.
• Alcohol: May worsen depressive symptoms, impair cognitive and motor function, and exacerbate gastrointestinal adverse effects. Limited or avoided use is recommended.

Practical Advice

• Take Viibryd exactly as prescribed, once daily with a meal. Food is essential for adequate absorption; taking vilazodone on an empty stomach reduces bioavailability by approximately 50%.
• Do not stop taking Viibryd abruptly. Gradual dose reduction is recommended to minimize the risk of discontinuation symptoms (dysphoric mood, irritability, dizziness, sensory disturbances, confusion, headache, insomnia).
• If a dose is missed, take it as soon as you remember on the same day. If it is almost time for the next dose, skip the missed dose and resume the normal schedule. Do not double doses.
• Monitor for signs of clinical worsening, suicidality, or unusual changes in behavior, especially during the first few months of therapy or at times of dose changes. Family members and caregivers should be alert to such changes and communicate them to the healthcare provider.
• Watch for symptoms of serotonin syndrome: agitation, confusion, hallucinations, rapid heart rate, fluctuating blood pressure, fever, excessive sweating, shivering, muscle stiffness, twitching, loss of coordination, nausea, vomiting, and diarrhea. Seek immediate medical attention if these occur.
• Inform all healthcare providers (including dentists and surgeons) that you are taking vilazodone, especially before any surgical procedure, because of the increased bleeding risk.
• Use caution when driving or operating machinery until you know how vilazodone affects you; it may impair cognitive and motor performance.
• Avoid or limit alcohol consumption during treatment.
• Store at room temperature (20‑25°C / 68‑77°F) with excursions permitted between 15‑30°C (59‑86°F). Keep in the original container, out of reach of children.
• Attend all scheduled follow‑up appointments. Regular monitoring of mood, response to treatment, and potential adverse effects is essential for safe and effective therapy.

Alternative Medications

• Vortioxetine (Trintellix®): Another multimodal antidepressant with SSRI activity combined with 5‑HT1A agonism, 5‑HT1B partial agonism, and 5‑HT3, 5‑HT1D, and 5‑HT7 antagonism. Also indicated for MDD in adults with evidence of cognitive benefit.
• Selective serotonin reuptake inhibitors (SSRIs): Fluoxetine (Prozac®), sertraline (Zoloft®), paroxetine (Paxil®), citalopram (Celexa®), and escitalopram (Lexapro®). First‑line agents for MDD; vilazodone may offer tolerability advantages, particularly regarding sexual dysfunction and weight gain.
• Serotonin‑norepinephrine reuptake inhibitors (SNRIs): Venlafaxine (Effexor XR®), desvenlafaxine (Pristiq®), duloxetine (Cymbalta®), and levomilnacipran (Fetzima®). Duloxetine and venlafaxine are particularly effective for patients with comorbid pain syndromes.
• Bupropion (Wellbutrin XL®, Wellbutrin SR®): An aminoketone antidepressant with primarily noradrenergic and dopaminergic activity. No serotonergic mechanism; favorable sexual side‑effect profile; also indicated for smoking cessation.
• Mirtazapine (Remeron®): A tetracyclic antidepressant with alpha‑2 adrenergic antagonist activity. Associated with sedation and weight gain, which may benefit patients with insomnia and appetite loss.
• Trazodone (Desyrel®): A serotonin antagonist and reuptake inhibitor (SARI); commonly used at low doses for insomnia and at higher doses for depression.
• Ketamine and esketamine (Spravato®): Rapid‑acting glutamate‑based treatments approved for treatment‑resistant depression; reserved for patients who have not responded to at least two conventional antidepressants.

Clinical Efficacy

The efficacy of Viibryd for the treatment of major depressive disorder was demonstrated in four multicenter, randomized, double‑blind, placebo‑controlled studies in adult outpatients (18‑70 years of age) who met DSM‑IV‑TR criteria for MDD. Three 8‑week studies evaluated vilazodone 40 mg/day, and one 10‑week study evaluated both 20 mg/day and 40 mg/day. In all four studies, vilazodone demonstrated statistically significant superiority over placebo as measured by the change from baseline to endpoint in the Montgomery‑Åsberg Depression Rating Scale (MADRS) total score, a validated ten‑item clinician‑rated scale. The placebo‑subtracted difference in MADRS score ranged from approximately ‑2.5 to ‑5.1 points across studies. In studies that assessed Clinical Global Impression — Severity (CGI‑S) scores, vilazodone 20 mg and 40 mg demonstrated significant superiority over placebo. Pooled analyses of pivotal trials found significantly higher rates of both response and remission with vilazodone compared to placebo, with efficacy demonstrated across all symptom domains of depression. Examination of population subgroups based on age, sex, and race did not reveal clear evidence of differential responsiveness. Meta‑analyses suggest that vilazodone's dual mechanism of action may confer a somewhat faster onset of antidepressant effect compared to conventional SSRIs, with some patients experiencing initial symptom improvement within 1‑2 weeks of reaching therapeutic doses, and a more favorable tolerability profile with regard to sexual function and weight gain.

Important:

Viibryd (vilazodone) is a prescription antidepressant that must be used under the supervision of a qualified healthcare provider. A comprehensive psychiatric evaluation, including screening for bipolar disorder and assessment of suicide risk, is necessary before initiating treatment. Antidepressants, including Viibryd, increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18‑24) with major depressive disorder and other psychiatric conditions. Closely monitor all patients for clinical worsening, suicidality, or unusual changes in behavior, especially during the initial few months of therapy and at times of dose adjustments. Viibryd is not approved for use in pediatric patients. Serotonin syndrome is a potentially life‑threatening condition; seek immediate medical attention if symptoms such as agitation, hallucinations, confusion, rapid heart rate, fever, muscle stiffness, or seizures develop. Do not use Viibryd with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOI therapy. Viibryd may increase the risk of bleeding, particularly when used with aspirin, NSAIDs, warfarin, or other medications that affect coagulation. Avoid abrupt discontinuation; the dose should be gradually tapered to minimize withdrawal symptoms. Viibryd must be taken with food to ensure adequate absorption. Alcohol should be limited or avoided during treatment. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the potential risks and benefits with their healthcare provider. Keep out of reach of children and never share this medication with others.

How to buy Generic Viibryd no prescription U.S. Online Pharmacy